home / stock / kura / kura articles

KURA Articles, Kura Oncology Inc. - From 01/30/24

Stock Information
Company Name: Kura Oncology Inc.
Stock Symbol: KURA
Market: NASDAQ
Website: kuraoncology.com
Menu
KURA KURA Quote KURA Short KURA News KURA Articles KURA Message Board
Get KURA Alerts

News, Short Squeeze, Breakout and More Instantly...
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia | Benzinga

– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ve...
Dow Edges Lower; US Composite PMI Rises In January | Benzinga

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 whi...

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session | Benzinga

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $1...

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today? | Benzinga

Kura Oncology Inc (NASDAQ:KURA) shares are trading higher after the announced $150 million private placement. The stock hit its 52-week h...
Textron Posts Upbeat Earnings, Joins ASML, Progressive And Other Big Stocks Moving Higher On Wednesday | Benzinga

U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Wednesday. Shares of Textron Inc. (NYSE: TXT) rose during Wednes...

Clinical Advancements In Kura Oncology's Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst | Benzinga

Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatmen...

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial | Benzinga

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizin...
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit | Benzinga

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizin...

Kura Oncology to Participate in Three Upcoming Investor Conferences | Benzinga

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizin...

Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients | Benzinga

Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head...
Previous 10 Next 10